Bicycle Therapeutics plc (BCYC)
BCYC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1761612/000110465926028971/0001104659-26-028971-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BCYC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United Kingdom |
| IPO year | 2019 |
| SEC CIK | 0001761612 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | United Kingdom |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $72.6M |
| Net income | -$219.0M |
| Operating income | -$247.1M |
| Net margin | -301.7% |
| Operating margin | -340.4% |
| Revenue growth | +105.8% |
| Cash | $628.1M |
| Total assets | $717.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $469.9M cash; operating cash flow -$43.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 70,093,761 (2026-10-31); 69,367,896 a year earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Cambridge, United Kingdom | PCAOB Form AP 2026-04-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $543K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $34.1M | -$10.5M | -$40.3M | $469.9M | No debt tags | $83.5M | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $629K | -$50.3M | -$49.6M | $510.1M | No debt tags | $61.2M | 10-Q 2026-07-30 |
| Q1 2026 2026-03-31 | $887K | -$60.8M | -$65.9M | $559.5M | No debt tags | $63.5M | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $48.0M | -$20.2M | -$19.3M | $628.1M | No debt tags | $72.6M | 10-K 2026-03-17 |
| Q3 2025 2025-09-30 | $11.7M | -$59.1M | -$71.2M | $648.3M | No debt tags | $28.3M | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $2.9M | -$79.0M | -$72.8M | $721.5M | No debt tags | $19.3M | 10-Q 2026-07-30 |
| Q1 2025 2025-03-31 | $10.0M | -$60.8M | -$86.4M | $793.0M | No debt tags | $25.7M | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $3.7M | -$51.9M | -$9.4M | $879.5M | No debt tags | $35.3M | 10-K 2026-03-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-08-14 |
| Latest annual report | 10-K | 2026-03-17 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report FORM 8-K | 8-K | 2026-10-29 |
| Latest proxy | DEF 14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 661 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.6% |
| 1 month | -7.2% |
| 3 months | -15.3% |
| Year to date | -52.4% |
| 1 year | -48.9% |
| From 52-week high | -55.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DRUG | Bright Minds Biosciences Inc. | $22.61 | -2.16% | $222.0M |
| IMRX | Immuneering Corporation | $3.52 | -5.12% | $228.0M |
| VNDA | Vanda Pharmaceuticals Inc. | $3.81 | -4.51% | $230.4M |
| VOGX | Vogenx Inc | $14.38 | -13.74% | $213.6M |
| AMRN | Amarin Corporation plc | $11.31 | -0.62% | $233.4M |
| ACIU | AC Immune SA | $2.09 | -1.88% | $212.7M |
| YARW | Yarrow Bioscience Inc. | $13.93 | -22.74% | $212.2M |
| CYPH | Cypherpunk Technologies Inc. | $1.93 | +2.94% | $207.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier